Next Article in Journal
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Previous Article in Journal
Invited Editorial: Despite COVID-19, Influenza Must Not Be Relegated to “Only the Sniffles”
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 8
Issue 3
10.3390/vaccines8030446
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season

by
Stephen I. Pelton
1,2,
Victoria Divino
3,*,
Drishti Shah
3,
Joaquin Mould-Quevedo
4,
Mitch DeKoven
3,
Girishanthy Krishnarajah
4 and
Maarten J. Postma
5,6,7
1
Department of Pediatrics, Boston University Schools of Medicine, Boston, MA 02118, USA
2
Maxwell Finland Laboratories, Boston Medical Center, Boston, MA 02118, USA
3
Department of Health Economics & Outcomes Research, Real-World Evidence, IQVIA, Falls Church, VA 22042, USA
4
Department of Global Market Access, Seqirus Vaccines Ltd., Summit, NJ 07901, USA
5
Unit of PharmacoTherapy, -Epidemiology & -Economics (PTE2), Department of Pharmacy, University of Groningen, 9700 Groningen, The Netherlands
6
Department of Health Sciences, University of Groningen, University Medical Centre Groningen (UMCG), 9700 Groningen, The Netherlands
7
Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, 9700 Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(3), 446; https://doi.org/10.3390/vaccines8030446
Submission received: 1 July 2020 / Revised: 2 August 2020 / Accepted: 3 August 2020 / Published: 7 August 2020
(This article belongs to the Section Influenza Virus Vaccines)
Browse Figures
Review Reports Versions Notes

Abstract

The influenza-related disease burden is highest among the elderly. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent influenza vaccine (aTIV) compared to other egg-based influenza vaccines (high-dose trivalent (TIV-HD), quadrivalent (QIVe-SD), and standard-dose trivalent (TIVe-SD)) against influenza-related and cardio-respiratory events among subjects aged ≥65 years for the 2017–2018 influenza season. This retrospective cohort analysis used prescription claims, professional fee claims, and hospital charge master data. Influenza-related hospitalizations/ER visits and office visits and cardio-respiratory events were assessed post-vaccination. Inverse probability of treatment weighting (IPTW) and Poisson regression were used to evaluate the adjusted rVE of aTIV compared to other vaccines. In an economic analysis, annualized follow-up costs were compared between aTIV and TIV-HD. The study was composed of 234,313 aTIV, 1,269,855 TIV-HD, 212,287 QIVe-SD, and 106,491 TIVe-SD recipients. aTIV was more effective in reducing influenza-related office visits and other respiratory-related hospitalizations/ER visits compared to the other vaccines. For influenza-related hospitalizations/ER visits, aTIV was associated with a significantly higher rVE compared to QIVe-SD and TIVe-SD and was comparable to TIV-HD. aTIV was also associated with a significantly higher rVE compared to TIVe-SD against hospitalizations/ER visits related to pneumonia and asthma/COPD/bronchial events. aTIV and TIV-HD were associated with comparable annualized all-cause and influenza-related costs. Adjusted analyses demonstrated a significant benefit of aTIV against influenza- and respiratory-related events compared to the other egg-based vaccines.
Keywords: influenza; influenza vaccine; adjuvanted influenza vaccine; relative vaccine effectiveness; elderly; retrospective studies influenza; influenza vaccine; adjuvanted influenza vaccine; relative vaccine effectiveness; elderly; retrospective studies

Share and Cite

MDPI and ACS Style

Pelton, S.I.; Divino, V.; Shah, D.; Mould-Quevedo, J.; DeKoven, M.; Krishnarajah, G.; Postma, M.J. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. Vaccines 2020, 8, 446. https://doi.org/10.3390/vaccines8030446

AMA Style

Pelton SI, Divino V, Shah D, Mould-Quevedo J, DeKoven M, Krishnarajah G, Postma MJ. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. Vaccines. 2020; 8(3):446. https://doi.org/10.3390/vaccines8030446

Chicago/Turabian Style

Pelton, Stephen I., Victoria Divino, Drishti Shah, Joaquin Mould-Quevedo, Mitch DeKoven, Girishanthy Krishnarajah, and Maarten J. Postma. 2020. "Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season" Vaccines 8, no. 3: 446. https://doi.org/10.3390/vaccines8030446

APA Style

Pelton, S. I., Divino, V., Shah, D., Mould-Quevedo, J., DeKoven, M., Krishnarajah, G., & Postma, M. J. (2020). Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season. Vaccines, 8(3), 446. https://doi.org/10.3390/vaccines8030446

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop